MCID: CTN003
MIFTS: 50

Cutaneous Lupus Erythematosus

Categories: Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Cutaneous Lupus Erythematosus

MalaCards integrated aliases for Cutaneous Lupus Erythematosus:

Name: Cutaneous Lupus Erythematosus 12 75 53 37 15 17
Lupus Erythematosus, Cutaneous 53 72
Lupus Erythematosus Cutaneous 55

Classifications:



External Ids:

Disease Ontology 12 DOID:0050169
KEGG 37 H01595
UMLS 72 C0024137

Summaries for Cutaneous Lupus Erythematosus

KEGG : 37
Cutaneous lupus erythematosus (CLE) is the skin-related form of lupus erythematosus (LE), with a broad spectrum of clinical manifestations and a variable course. CLE is a frequent finding in patients with systemic lupus erythematosus (SLE) and can also exist as a single entity without associated systemic autoimmunity (LE-specific skin disease). Despite ongoing research into the cause of CLE, it remains unclear how CLE relates to SLE pathogenesis. LE-specific skin disease includes the subtypes of CLE such as acute cutaneous LE (ACLE), subacute cutaneous LE (SCLE), chronic cutaneous LE (CCLE), and intermittent CLE (ICLE). ACLE is characterized by malar rash or maculopapular eruption on sun exposed areas. SCLE characteristically presents as annular or psoriasiform plaques in a photo distribution. CCLE can be further divided into discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain LE (CLE), and LE tumidus (LET). The pathogenesis of CLE is multifactorial and involves genetic predisposition, environmental triggers, and abnormalities in the immune response. It has been reported that many genetic risk factors for CLE involve HLA or interferon-related pathways. Corticosteroids and antimalarials were considered as the most suitable and effective systemic drugs for CLE patients.

MalaCards based summary : Cutaneous Lupus Erythematosus, also known as lupus erythematosus, cutaneous, is related to subacute cutaneous lupus erythematosus and lupus erythematosus, and has symptoms including pruritus and exanthema. An important gene associated with Cutaneous Lupus Erythematosus is CXCR3 (C-X-C Motif Chemokine Receptor 3), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs belimumab and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and lung, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A lupus erythematosus that causes skin lesions on parts of the body that are exposed to sunlight.

Wikipedia : 75 Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes... more...

Related Diseases for Cutaneous Lupus Erythematosus

Diseases in the Cutaneous Lupus Erythematosus family:

Rare Cutaneous Lupus Erythematosus Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus

Diseases related to Cutaneous Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 323)
# Related Disease Score Top Affiliating Genes
1 subacute cutaneous lupus erythematosus 34.3 TRIM21 TNF EEA1 CD70
2 lupus erythematosus 31.4 TRIM21 TREX1 TNF CD40LG
3 chilblain lupus 1 30.5 TRIM21 TREX1 MX1
4 sarcoidosis 1 30.4 TNF IL18 CXCR3
5 rheumatic disease 30.3 TRIM21 TNF IL18 CD40LG
6 sialadenitis 30.3 TRIM21 TNF
7 systemic scleroderma 30.3 TRIM21 SELE CD40LG
8 vasculitis 30.2 TNF SELE ICAM1 CD40LG
9 dermatitis, atopic 30.0 TNF SELE IL18 ICAM1
10 lymphadenitis 30.0 TNF IL18 ICAM1 CXCR3
11 acute graft versus host disease 29.9 TNF IL18 GZMB
12 actinic prurigo 29.8 TNF SELE ICAM1
13 cerebrovascular disease 29.8 TNF SELE ICAM1
14 proteasome-associated autoinflammatory syndrome 1 29.7 TNF SELE IL18 ICAM1
15 erythema multiforme 29.6 TNF ICAM1 GZMB CXCR3
16 common variable immunodeficiency 29.5 TNF CD70 CD40LG
17 bronchiolitis obliterans 29.5 TNF GZMB CXCR3
18 alopecia areata 29.5 TNF ICAM1 GZMB
19 contact dermatitis 29.4 TNF SELE ICAM1 CXCR3
20 lichen planus 29.2 TNF MX1 ICAM1 GZMB CXCR3
21 rheumatoid arthritis 29.1 TNF SELE IL18 ICAM1 CD40LG
22 systemic lupus erythematosus 27.2 TRIM21 TREX1 TNF SELE MX1 IL18
23 chronic cutaneous lupus erythematosus 12.6
24 rare cutaneous lupus erythematosus 12.6
25 obsolete: acute cutaneous lupus erythematosus 12.5
26 lupus erythematosus tumidus 12.0
27 neonatal lupus erythematosus 11.8
28 autoimmune disease 10.8
29 discoid lupus erythematosus 10.8
30 skin disease 10.7
31 encephalitozoonosis 10.6 TNF MX1
32 systemic onset juvenile idiopathic arthritis 10.6 TNF IL18
33 exanthem 10.6
34 alopecia 10.6
35 dermatomyositis 10.6
36 listeria meningitis 10.5 TNF IL18
37 stachybotrys chartarum 10.5 TNF IL18
38 panniculitis 10.5
39 scleritis 10.5 TNF SELE
40 inflammatory bowel disease 3 10.4 TNF IL18
41 diffuse infiltrative lymphocytosis syndrome 10.4 TRIM21 TNF
42 retinitis pigmentosa 60 10.4 TNF SELE
43 connective tissue disease 10.4
44 stevens-johnson syndrome/toxic epidermal necrolysis 10.4
45 orofacial granulomatosis 10.4 TNF CXCR3
46 intermediate uveitis 10.4 TNF CXCR3
47 enthesopathy 10.4
48 raynaud phenomenon 10.4
49 shwartzman phenomenon 10.4 TNF ICAM1
50 mycoplasma pneumoniae pneumonia 10.3 TNF IL18

Graphical network of the top 20 diseases related to Cutaneous Lupus Erythematosus:



Diseases related to Cutaneous Lupus Erythematosus

Symptoms & Phenotypes for Cutaneous Lupus Erythematosus

UMLS symptoms related to Cutaneous Lupus Erythematosus:


pruritus, exanthema

GenomeRNAi Phenotypes related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 CD40LG CD70 GZMB ICAM1 IL18 MX1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 CD40LG CD70 GZMB ICAM1 IL18 MX1

MGI Mouse Phenotypes related to Cutaneous Lupus Erythematosus:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.91 CD40LG CD70 CXCR3 ICAM1 IL18 SELE
2 cardiovascular system MP:0005385 9.87 CD40LG CXCR3 ICAM1 IL18 SELE TNF
3 homeostasis/metabolism MP:0005376 9.81 CD40LG CXCR3 ICAM1 IL18 KRT15 SELE
4 immune system MP:0005387 9.61 CD40LG CD70 CXCR3 ICAM1 IL18 SELE
5 integument MP:0010771 9.17 CD40LG ICAM1 IL18 SELE TNF TREX1

Drugs & Therapeutics for Cutaneous Lupus Erythematosus

Drugs for Cutaneous Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
belimumab Approved Phase 4 356547-88-1 5957 10451420
2 Immunologic Factors Phase 4
3 Immunosuppressive Agents Phase 4
4
Hydroxychloroquine Approved Phase 3 118-42-3 3652
5 Anti-Infective Agents Phase 3
6 Antiparasitic Agents Phase 3
7 Antimalarials Phase 3
8 Antiprotozoal Agents Phase 3
9 Radiation-Protective Agents Phase 3
10 Protective Agents Phase 3
11 Sunscreening Agents Phase 3
12
Dimethyl fumarate Approved, Investigational Phase 2 624-49-7 5271565 637568
13
Norflurane Approved, Experimental Phase 2 811-97-2
14
Etanercept Approved, Investigational Phase 2 185243-69-0
15
Apremilast Approved, Investigational Phase 1, Phase 2 608141-41-9 11561674
16
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
17
Tofacitinib Approved, Investigational Phase 1, Phase 2 477600-75-2
18
Abatacept Approved Phase 2 332348-12-6 10237
19
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
20
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
21
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
22
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
23
Alitretinoin Approved, Investigational Phase 2 5300-03-8 444795 449171
24
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
25
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
26
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 6221 5280795
27
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
28
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
29
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
30
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
31 Analgesics Phase 2
32 Anti-Inflammatory Agents Phase 2
33 Analgesics, Non-Narcotic Phase 2
34 Peripheral Nervous System Agents Phase 2
35 Anti-Inflammatory Agents, Non-Steroidal Phase 2
36 Gastrointestinal Agents Phase 2
37 Phosphodiesterase 5 Inhibitors Phase 1, Phase 2
38 Phosphodiesterase Inhibitors Phase 1, Phase 2
39 Phosphodiesterase 4 Inhibitors Phase 1, Phase 2
40 Antirheumatic Agents Phase 2
41 Lipid Regulating Agents Phase 2
42 Vitamin B9 Phase 2
43 Nicotinic Acids Phase 2
44 Vitamin B3 Phase 2
45 Folate Phase 2
46 Vitamin B Complex Phase 2
47 Hypolipidemic Agents Phase 2
48 Vasodilator Agents Phase 2
49 Antimetabolites Phase 2
50 Protein Kinase Inhibitors Phase 1, Phase 2

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Recruiting NCT02270970 Phase 4
2 Efficacy of 595 nm Pulsed-dye Laser as an Adjunctive Treatment of Discoid Lupus Erythematosus, A Randomized, Patient/Assessor Blinded Placebo Control Trial Unknown status NCT03178188 Phase 2, Phase 3
3 A Randomized, Double Blind, Baseline Controlled Study Using Placebo as Reference for Assessing the Efficacy and Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus in the Presence of Active Lupus Erythematosus Specific Skin Lesion Completed NCT01551069 Phase 3 hydroxychloroquine (Z0188);Placebo
4 Photoprotective Effects of the RV 2457C Sunscreen Milk in Photoinduced Cutaneous Lupus Erythematosus Completed NCT00470912 Phase 3 sunscreen RV 2547C
5 A Phase Ib Study of Milatuzumab Administered Subcutaneously in Patients With Active Systemic Lupus Erythematosus (SLE) Unknown status NCT01845740 Phase 1, Phase 2 milatuzumab;Placebo
6 A Multi-center, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy and Tolerability of KRP203 in Patients With Active Subacute Cutaneous Lupus Erythematosus Completed NCT01294774 Phase 2 KRP203 - 1.2mg;Placebo to KRP203 - 1.2 mg
7 A Phase 2, Pilot, Multicenter, Sequential, Ascending Dose Study to Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus Completed NCT01300208 Phase 2 CC-11050
8 The Efficacy of Topical Tacrolimus in the Treatment of Cutaneous Lupus Erythematosus - a Multi-Center-Trial Completed NCT00317681 Phase 2 Tacrolimus ointment
9 Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus: A Mono-Centre, Open-Label, Prospective Pilot Study Completed NCT01352988 Phase 2 Fumaric acid esters
10 Single Blind, Controlled, Single-Center Study of Laser Treatment in Cutaneous Lupus Erythematosus Completed NCT00523588 Phase 2
11 A Single Arm, Phase II Open Label Trial to Investigate the Efficacy and Safety of Intra-dermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus Completed NCT02656082 Phase 2 Etanercept
12 Clinical and Immune-modulating Effects of CC-10004 in Discoid Lupus Erythematosus Completed NCT00708916 Phase 1, Phase 2 CC-10004
13 An Open-label Study for Assessing the Efficacy and Safety of Nicotinamide Treatment for Lupus-associated Skin Lesions in Patients With Cutaneous Lupus Erythematosus or Systemic Lupus Erythematosus Recruiting NCT03260166 Phase 2 nicotinamide
14 A 3-part Open-label Study Assessing Safety, Tolerability, Pharmacokinetic and -Dynamic Profiles, and Efficacy of Tofacitinib in Young Adults From Age 18 to 45 With Moderate to Severe Skin Involvement Due to Lupus Recruiting NCT03288324 Phase 1, Phase 2 Tofacitinib
15 Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches (The ABC Study) Recruiting NCT02270957 Phase 2
16 A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) Active, not recruiting NCT03134222 Phase 2 Filgotinib;Lanraplenib;Filgotinib placebo;Lanraplenib placebo
17 A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations Active, not recruiting NCT02847598 Phase 2 BIIB059;Placebo
18 Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus: A Multicentre, Open-Label, Prospective Pilot Study Terminated NCT01407679 Phase 2 Alitretinoin
19 Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus Terminated NCT01498406 Phase 2
20 A Double-blind (Sponsor Unblinded) Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of Repeat Dosing of GSK2646264 in Cutaneous Lupus Erythematosus Patients Completed NCT02927457 Phase 1 GSK2646264 1%;Placebo
21 A Phase 1, Double-blind, Placebo-controlled, Multiple Intravenous, Ascending-Dose Study of CNTO 136 to Evaluate Safety and Pharmacokinetics in Subjects With Cutaneous Lupus Erythematosus and to Evaluate Safety and Pharmacokinetics in a Cohort of Subjects With Systemic Lupus Erythematosus Completed NCT01702740 Phase 1 1 mg/kg CNTO 136;4 mg/kg CNTO 136;10 mg/kg CNTO 136;Placebo
22 A Phase 1 Study of CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy Completed NCT02652546 Phase 1 Assess Safety;Effect of drug on viral load;Effect of drug on T-cell count;Effect of drug on inflammatory biomarkers
23 A Phase 1 Randomized, Placebo-Controlled, Blinded, Multiple Ascending Dose Study to Evaluate VIB7734 in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis Recruiting NCT03817424 Phase 1 VIB7734;Placebo
24 A Randomized, Subject And Investigator-Blinded (Sponsor-Open), Placebo-Controlled Study To Evaluate The Safety, Tolerability, And Preliminary Efficacy Of Multiple Ascending Doses Of PD- 0360324 In Subjects With Active Cutaneous Lupus Erythematosus (CLE) Terminated NCT01470313 Phase 1 PD-0360324;Placebo
25 A Phase I, Open-Label, Dose Escalation Trial Exploring the Safety and Tolerability of Autologous Polyclonal Regulatory T Cell Therapy in Adults With Active Cutaneous Lupus (ALE08) Terminated NCT02428309 Phase 1
26 A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus Terminated NCT01389895 Phase 1 AMG 557;AMG 557 Placebo
27 Longitudinal Study of Skin And Systemic Biomarkers In Subjects With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers Completed NCT02034344
28 Cross-Sectional Study in Subjects With Active Cutaneous Lupus Erythematosus Completed NCT01923415
29 Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus Completed NCT01629784
30 Interdisciplinary Study Group of Lupus Erythematosus Completed NCT00420173
31 A Pilot Study to Evaluate Using Tape Harvesting to Collect Ribonucleic Acid From the Upper Epidermis of Healthy Volunteers and Subjects With Discoid Lupus, Subjects With Subacute Cutaneous Lupus, and Subjects With Atopic Dermatitis Completed NCT02125695
32 Investigation of the Efficacy of Different Sunscreens in Patients With Photosensitive Cutaneous Lupus Erythematosus Completed NCT01146444
33 Evaluation of Lenalidomide (REVLIMID®) in Cutaneous LE: A Prospective, Non Controlled, Open Label Pilot Study to Evaluate the Off-Label Use of the FDA-approved Drug Lenalidomide (REVLIMID®) in Patients With Cutaneous Lupus Erythematosus Completed NCT00633945 lenalidomide (Revlimid®)
34 Proof-of-Concept Study of IVIg Efficacy in Patients With Cutaneous Lupus Erythematosus Completed NCT01841619 Early Phase 1 IVIg
35 Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus Recruiting NCT01510067
36 Low-dose UVA1 Radiation in Cutaneous Lupus Patients Recruiting NCT01776190
37 Duke Lupus Registry Recruiting NCT00512694
38 A Comparative Study of the Efficacy of 532nm Laser and 1064 nm Laser in the Treatment of Cutaneous Lupus Erythematous Versus Topical Corticosteroids Alone Recruiting NCT03639857 Topical corticosteroid
39 Molecular Studies on Cutaneous Lupus Recruiting NCT01266915
40 European Society of Cutaneous Lupus Erythematosus Enrolling by invitation NCT00420121
41 Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid Terminated NCT01559155
42 Evaluation of the Therapeutic Effect and Local Tolerability of Elidel® Cream 1% (Pimecrolimus) in Chronic Discoid Lupus Erythematosus (dLE) or Subacute Cutaneous Lupus Erythematosus (scLE) Withdrawn NCT00222183 Elidel (pimecrolimus)

Search NIH Clinical Center for Cutaneous Lupus Erythematosus

Genetic Tests for Cutaneous Lupus Erythematosus

Anatomical Context for Cutaneous Lupus Erythematosus

MalaCards organs/tissues related to Cutaneous Lupus Erythematosus:

41
Skin, T Cells, Lung, Heart, Kidney, Testes, Breast

Publications for Cutaneous Lupus Erythematosus

Articles related to Cutaneous Lupus Erythematosus:

(show top 50) (show all 1520)
# Title Authors PMID Year
1
CXCR3 <-> ligand-mediated skin inflammation in cutaneous lichenoid graft-versus-host disease. 9 38
18280341 2008
2
Elevated soluble E-selectin in cutaneous lupus erythematosus. 9 38
10599337 1999
3
Relationship between heat shock protein induction and the binding of antibodies to the extractable nuclear antigens on cultured human keratinocytes. 9 38
8345220 1993
4
Binding of antibodies to the extractable nuclear antigens SS-A/Ro and SS-B/La is induced on the surface of human keratinocytes by ultraviolet light (UVL): implications for the pathogenesis of photosensitive cutaneous lupus. 9 38
2132545 1990
5
Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. 38
31399711 2019
6
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis-Like Lupus Erythematosus. 38
29912772 2019
7
Metastatic prostate cancer presenting as subacute cutaneous lupus erythematosus. 38
31407804 2019
8
Proton Pump Inhibitor-Induced Subacute Cutaneous Lupus Erythematosus. 38
31427196 2019
9
Treatment of exfoliative cutaneous lupus erythematosus in a German shorthaired pointer dog with mycophenolate mofetil. 38
31038261 2019
10
Molecular Profiling of Cutaneous Lupus Lesions Identifies Subgroups Distinct from Clinical Phenotypes. 38
31426521 2019
11
Are there distinct clinical and pathological features distinguishing idiopathic from drug-induced subacute cutaneous lupus erythematosus? A European retrospective multicenter study. 38
30763648 2019
12
Intravenous immunoglobulin G use in patients with chronic inflammatory demyelinating polyneuropathy: An uncommon cause of drug-induced discoid lupus erythematosus. 38
30734274 2019
13
Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review. 38
31228033 2019
14
An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: A systematic review. 38
31306730 2019
15
Inflammatory chemokine profiles and their correlations with effector CD4 T cell and regulatory cell subpopulations in cutaneous lupus erythematosus. 38
30903869 2019
16
JAAD Game Changers: The incidence of herpes zoster in cutaneous lupus erythematosus (CLE), dermatomyositis (DM), pemphigus vulgaris (PV), and bullous pemphigoid (BP). 38
30521827 2019
17
Primary Cutaneous Clonal CD8+ T-Cell Lymphoproliferative Disorder Associated With Immunodeficiency due to RAG1 Mutation. 38
31313695 2019
18
Periorbital swelling and episcleritis may be a sign of cutaneous lupus erythematosus. 38
31360503 2019
19
Subacute cutaneous lupus erythematosus induced by gemcitabine in 2 patients with pancreatic cancer. 38
31317065 2019
20
Regulatory T cells in inflammatory skin disease: from mice to humans. 38
30865268 2019
21
Cutaneous lupus erythematosus induced by radiotherapy for breast carcinoma. 38
31305003 2019
22
Spectrum of cutaneous lupus erythematosus in South Africans with systemic lupus erythematosus. 38
31215844 2019
23
Validation and reliability of a disease-specific quality-of-life measure in patients with cutaneous lupus erythematosus. 38
30637718 2019
24
Fatigue in systemic lupus erythematosus and other autoimmune skin diseases. 38
30269332 2019
25
A review of the evidence and cost of therapies for cutaneous lupus erythematosus. 38
31042129 2019
26
Clinical characteristics of pediatric cutaneous lupus erythematosus: experience from a tertiary referral center in Korea. 38
31112454 2019
27
Chronic Cutaneous Lupus Erythematosus: Depression Burden and Associated Factors. 38
30877492 2019
28
Usefulness of Pulsed Dye Laser in Cutaneous Lupus Erythematosus. 38
30213381 2019
29
Understanding cutaneous lupus erythematosus: a step forward. 38
31157430 2019
30
Cutaneous effects of antihypertensive drugs. 38
31195782 2019
31
Rowell's Syndrome Triggered by Omeprazole. 38
31351509 2019
32
An Unusual Morphological and Distribution Pattern of Chronic Cutaneous Lupus Erythematosus. 38
31149584 2019
33
Subacute Cutaneous Lupus Erythematosus in a Male Patient on Multiple Antiepileptics Unmasked by Melatonin. 38
31136412 2019
34
Cutaneous lupus erythematosus patients with a negative antinuclear antibody meeting the American College of Rheumatology and/or Systemic Lupus International Collaborating Clinics criteria for systemic lupus erythematosus. 38
31058462 2019
35
A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus. 38
31025748 2019
36
Utility of CD123 immunohistochemistry in differentiating lupus erythematosus from cutaneous T cell lymphoma. 38
30597607 2019
37
Diagnosing Pemphigus Foliaceus: A Rare Blistering Disease Masquerading as a Common Dermatologic Disorder. 38
30215775 2019
38
Hypersensitive IFN Responses in Lupus Keratinocytes Reveal Key Mechanistic Determinants in Cutaneous Lupus. 38
30745462 2019
39
Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review. 38
30489484 2019
40
Autoantibody profile and clinical patterns in 619 Italian patients with cutaneous lupus erythematosus. 38
29924416 2019
41
Subacute cutaneous lupus erythematosus leukoderma treated with melanocyte-keratinocyte transplantation procedure. 38
30932304 2019
42
Varied responses to and efficacies of hydroxychloroquine treatment according to cutaneous lupus erythematosus subtypes in Japanese patients. 38
30719729 2019
43
Delineating the Healthy Human Skin UV Response and Early Induction of Interferon Pathway in Cutaneous Lupus Erythematosus. 38
30974166 2019
44
Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. 38
30645203 2019
45
Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature. 38
30921233 2019
46
Subacute cutaneous lupus erythematosus triggered by an antiviral treatment combination for hepatitis C virus infection. 38
30394571 2019
47
Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation. 38
30673078 2019
48
Neonatal cutaneous lupus erythematosus. 38
30580253 2019
49
Increased Myeloid Dendritic Cells and TNF-α Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus. 38
30227141 2019
50
Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus-An Ongoing Need for International Consensus and Collaborations. 38
30243657 2019

Variations for Cutaneous Lupus Erythematosus

Expression for Cutaneous Lupus Erythematosus

Search GEO for disease gene expression data for Cutaneous Lupus Erythematosus.

Pathways for Cutaneous Lupus Erythematosus

Pathways related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.76 TRIM21 TREX1 TNF MX1 IL18 ICAM1
2
Show member pathways
12.98 TRIM21 TNF MX1 IL18 ICAM1 CD70
3
Show member pathways
12.57 TNF IL18 ICAM1 GZMB CD40LG
4 12.04 TNF GZMB CD40LG
5 12.02 TNF IL18 EEA1
6 11.91 SELE ICAM1 CD40LG
7 11.88 TNF SELE ICAM1
8 11.77 TNF IL18 ICAM1
9 11.75 TNF SELE ICAM1
10 11.67 TNF SELE ICAM1
11 11.66 TNF ICAM1 CD40LG
12 11.6 TNF IL18 ICAM1
13 11.46 TNF IL18 GZMB CXCR3
14 11.27 TNF IL18 ICAM1
15
Show member pathways
11.26 TNF SELE ICAM1 CD40LG
16 11.11 TNF IL18
17 10.98 IL18 ICAM1
18 10.92 TNF IL18
19 10.9 TNF IL18 CD70 CD40LG
20 10.82 TNF IL18 CD70 CD40LG
21 10.82 TNF SELE IL18 ICAM1
22 10.75 TNF ICAM1
23 10.71 TNF SELE IL18 ICAM1 CD40LG

GO Terms for Cutaneous Lupus Erythematosus

Cellular components related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.43 TNF SELE ICAM1 CXCR3 CD70 CD40LG
2 external side of plasma membrane GO:0009897 8.92 TNF ICAM1 CXCR3 CD40LG

Biological processes related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.72 TNF IL18 CXCR3 CD70 CD40LG
2 leukocyte migration GO:0050900 9.7 TNF SELE ICAM1
3 tumor necrosis factor-mediated signaling pathway GO:0033209 9.61 TNF CD70 CD40LG
4 inflammatory response GO:0006954 9.55 TNF SELE IL18 CXCR3 CD40LG
5 negative regulation of myoblast differentiation GO:0045662 9.51 TNF IL18
6 natural killer cell mediated cytotoxicity GO:0042267 9.49 IL18 GZMB
7 leukocyte tethering or rolling GO:0050901 9.48 TNF SELE
8 regulation of type I interferon production GO:0032479 9.46 TRIM21 TREX1
9 positive regulation of neuroinflammatory response GO:0150078 9.4 TNF IL18
10 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.37 TNF ICAM1
11 regulation of immunoglobulin secretion GO:0051023 9.26 TNF CD40LG
12 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.26 TNF IL18 ICAM1 CD40LG
13 leukocyte cell-cell adhesion GO:0007159 8.8 SELE ICAM1 CD40LG

Molecular functions related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 TNF IL18 CD70 CD40LG
2 tumor necrosis factor receptor binding GO:0005164 8.8 TNF CD70 CD40LG

Sources for Cutaneous Lupus Erythematosus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....